NASDAQ:GNCA Genocea Biosciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.02 0.00 (0.00%) (As of 07/5/2022 12:00 AM ET) Add Compare Share Today's Range$0.02▼$0.0250-Day Range$0.01▼$0.4152-Week Range$0.01▼$2.27Volume83,513 shsAverage Volume2.36 million shsMarket Capitalization$933,807.00P/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Genocea Biosciences MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside18,767.9% Upside$3.00 Price TargetShort InterestBearish13.58% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$781,461 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.26) to ($1.00) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.41 out of 5 stars 3.0 Analyst's Opinion Consensus RatingGenocea Biosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Genocea Biosciences has a forecasted upside of 18,767.9% from its current price of $0.02.Amount of Analyst CoverageGenocea Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.58% of the float of Genocea Biosciences has been sold short.Short Interest Ratio / Days to CoverGenocea Biosciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genocea Biosciences has recently increased by 118.90%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGenocea Biosciences does not currently pay a dividend.Dividend GrowthGenocea Biosciences does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GNCA. Previous Next 1.1 News and Social Media Coverage News SentimentGenocea Biosciences has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Genocea Biosciences this week, compared to 0 articles on an average week.Search InterestOnly 3 people have searched for GNCA on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Genocea Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Genocea Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $781,461.00 in company stock.Percentage Held by InsidersOnly 1.61% of the stock of Genocea Biosciences is held by insiders.Percentage Held by Institutions59.25% of the stock of Genocea Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Genocea Biosciences are expected to decrease in the coming year, from ($0.26) to ($1.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genocea Biosciences is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Genocea Biosciences is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGenocea Biosciences has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GNCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address About Genocea Biosciences (NASDAQ:GNCA) StockGenocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts.Read More GNCA Stock News HeadlinesJuly 2, 2022 | americanbankingnews.comGenocea Biosciences (NASDAQ:GNCA) Now Covered by StockNews.comJune 23, 2022 | americanbankingnews.comGenocea Biosciences (NASDAQ:GNCA) Receives New Coverage from Analysts at StockNews.comJune 15, 2022 | americanbankingnews.comGenocea Biosciences (NASDAQ:GNCA) Coverage Initiated by Analysts at StockNews.comMay 27, 2022 | seekingalpha.comGRPN, GNCA and LAB among mid-day moversMay 25, 2022 | finance.yahoo.comGenocea Biosciences to shut downMay 24, 2022 | finance.yahoo.comGenocea Closes Shop, Delists From NASDAQMay 24, 2022 | finance.yahoo.comThree weeks after layoffs, Genocea shuts down entirelyMay 24, 2022 | seekingalpha.comGenocea stock crashes 64% on winding down of operations, Nasdaq delistingMay 24, 2022 | finance.yahoo.comGenocea Announces Wind Down of Operations and Delisting From NASDAQMay 2, 2022 | finance.yahoo.comGenocea cuts two-thirds of staff, explores a saleApril 29, 2022 | seekingalpha.comGenocea stock plunges on cutting workforce by 65% and exploring sale or merger alternatives; Stifel cuts PT to $0.16April 28, 2022 | finance.yahoo.comGenocea Initiates Restructuring and Announces Plan to Explore Strategic AlternativesApril 11, 2022 | finance.yahoo.comImplied Volatility Surging for Genocea (GNCA) Stock OptionsApril 8, 2022 | uk.investing.comGenocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor PatientsApril 8, 2022 | finance.yahoo.comGenocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022April 4, 2022 | finance.yahoo.comGenocea Biosciences to Host Investor WebinarMarch 14, 2022 | finance.yahoo.comGenocea to Present at the 32nd Annual Oppenheimer Healthcare ConferenceMarch 10, 2022 | seekingalpha.comGenocea Biosciences GAAP EPS of -$0.19 misses by $0.01March 10, 2022 | apnews.comGenocea Biosciences: Q4 Earnings SnapshotMarch 10, 2022 | finance.yahoo.comGenocea Provides Fourth Quarter 2021 Corporate UpdateMarch 9, 2022 | seekingalpha.comGenocea Biosciences Q4 2021 Earnings PreviewMarch 9, 2022 | benzinga.comGenocea Biosciences Earnings PreviewMarch 8, 2022 | finance.yahoo.comGenocea to Present Clinical and Preclinical Data at AACR Annual MeetingMarch 3, 2022 | finance.yahoo.comGenocea to Host Fourth Quarter 2021 Corporate Update Conference Call & WebcastFebruary 10, 2022 | finance.yahoo.comGenocea to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNCA CUSIPN/A CIK1457612 Webwww.genocea.com Phone(617) 876-8191Fax617-876-8192Employees74Year FoundedN/ACompany Calendar Last Earnings10/27/2021Today7/06/2022Next Earnings (Estimated)7/27/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$3.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+18,767.9%Consensus RatingHold Rating Score (0-4)2 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,200,000.00 Net MarginsN/A Pretax Margin-1,946.15% Return on Equity-182.88% Return on Assets-62.76% Debt Debt-to-Equity Ratio0.24 Current Ratio1.35 Quick Ratio1.35 Sales & Book Value Annual Sales$1.64 million Price / Sales0.57 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book0.03Miscellaneous Outstanding Shares58,730,000Free Float57,788,000Market Cap$933,807.00 OptionableOptionable Beta2.26 Genocea Biosciences Frequently Asked Questions Should I buy or sell Genocea Biosciences stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genocea Biosciences in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Genocea Biosciences stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GNCA, but not buy additional shares or sell existing shares. View analyst ratings for Genocea Biosciences or view top-rated stocks. What is Genocea Biosciences' stock price forecast for 2022? 2 equities research analysts have issued twelve-month price targets for Genocea Biosciences' stock. Their GNCA stock forecasts range from $3.00 to $3.00. On average, they anticipate Genocea Biosciences' share price to reach $3.00 in the next year. This suggests a possible upside of 18,767.9% from the stock's current price. View analysts' price targets for Genocea Biosciences or view top-rated stocks among Wall Street analysts. How has Genocea Biosciences' stock price performed in 2022? Genocea Biosciences' stock was trading at $1.16 on January 1st, 2022. Since then, GNCA stock has decreased by 98.6% and is now trading at $0.0159. View the best growth stocks for 2022 here. Are investors shorting Genocea Biosciences? Genocea Biosciences saw a increase in short interest in May. As of May 31st, there was short interest totaling 3,590,000 shares, an increase of 118.9% from the May 15th total of 1,640,000 shares. Based on an average daily trading volume, of 8,010,000 shares, the days-to-cover ratio is presently 0.4 days. Approximately 13.6% of the shares of the stock are sold short. View Genocea Biosciences' Short Interest. When is Genocea Biosciences' next earnings date? Genocea Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast for Genocea Biosciences. How were Genocea Biosciences' earnings last quarter? Genocea Biosciences, Inc. (NASDAQ:GNCA) released its quarterly earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.15. The biotechnology company earned $1.64 million during the quarter. During the same quarter last year, the business posted ($0.26) earnings per share. View Genocea Biosciences' earnings history. Who are Genocea Biosciences' key executives? Genocea Biosciences' management team includes the following people: Mr. William D. Clark M.B.A., Pres, CEO & Director (Age 53, Pay $837.42k)Dr. Jessica Baker Flechtner Ph.D., Chief Scientific Officer (Age 50, Pay $585.18k)Ms. Diantha Duvall CPA, M.B.A., CFO & Sec. (Age 50)Ms. Jacquelyn L. Sumer, Chief Legal & Compliance Officer (Age 44) What is William Clark's approval rating as Genocea Biosciences' CEO? 5 employees have rated Genocea Biosciences CEO William Clark on Glassdoor.com. William Clark has an approval rating of 82% among Genocea Biosciences' employees. Who are some of Genocea Biosciences' key competitors? Some companies that are related to Genocea Biosciences include Cornwall Resources (CORC), Advanced Life Sciences (ADLS), AVAX Technologies (AVXT), Compugen (CGEN), Gene Biotherapeutics (CRXM), Innate Pharma (IPHYF), Mymetics (MYMX), Neurobiological Technologies (NTII), Omni Bio Pharmaceutical (OMBP), Panacos Pharmaceuticals (PANC), Protide Pharmaceuticals (PPMD), Quantum Genomics Société Anonyme (QNNTF), Tengion (TNGNQ) and VIA Pharmaceuticals (VIAP). View all of GNCA's competitors. What other stocks do shareholders of Genocea Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO). What is Genocea Biosciences' stock symbol? Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA." How do I buy shares of Genocea Biosciences? Shares of GNCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Genocea Biosciences' stock price today? One share of GNCA stock can currently be purchased for approximately $0.02. How much money does Genocea Biosciences make? Genocea Biosciences (NASDAQ:GNCA) has a market capitalization of $933,807.00 and generates $1.64 million in revenue each year. The biotechnology company earns $-33,200,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. How many employees does Genocea Biosciences have? Genocea Biosciences employs 74 workers across the globe. How can I contact Genocea Biosciences? Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The official website for Genocea Biosciences is www.genocea.com. The biotechnology company can be reached via phone at (617) 876-8191, via email at ir@genocea.com, or via fax at 617-876-8192. This page (NASDAQ:GNCA) was last updated on 7/6/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
